Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study - 11/02/20
Abbreviations used : CI, ICI, irAE
Drs Molina and Allen are cofirst authors. |
|
Drs Dougan and Chen are cosenior authors. |
|
Funding sources: None. |
|
Disclosure: Dr Dougan receives research funding from Novartis and is a consultant for Genentech, unrelated to the current study. Mr Molina and Drs Allen, Hughes, Zubiri, Lee, Mooradian, Reynolds, and Chen have no conflicts of interest to declare. |
|
This study was presented as an oral presentation at the Medical Dermatology Society Annual Meeting, Washington, DC, February 28, 2019, and the 24th Meeting of the World Congress of Dermatology, Milan, Italy, June 13, 2019. |
|
Reprints not available from the authors. |
Vol 82 - N° 3
P. 743-746 - mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?